Halozyme Therapeutics (HALO) Cash from Operations (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Cash from Operations data on file, last reported at 180078000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations rose 16.77% year-over-year to 180078000.0 in Q1 2026; TTM through Mar 2026 was 677415000.0, a 34.45% increase from a year earlier, with the FY2025 full-year figure at 651558000.0, up 36.01% from the prior year.
• Cash from Operations for Q1 2026 stood at 180078000.0, down from 219029000.0 in the prior quarter.
• Over the last five years, Cash from Operations for HALO reached as high as 219029000.0 in Q4 2025 and fell as low as 40225000.0 in Q2 2022.
• Historically, Cash from Operations has averaged 114081235.29 across 5 years, with a median of 102354000.0 in 2023.
• Across the five-year window, Cash from Operations tumbled 42.8% in 2022 and surged 90.15% in 2023, its largest moves.
• Year by year, Cash from Operations stood at 82453000.0 in 2022, then increased by 24.14% to 102354000.0 in 2023, then jumped by 74.36% to 178467000.0 in 2024, then gained by 22.73% to 219029000.0 in 2025, then slipped by 17.78% to 180078000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 180078000.0 in Q1 2026, 219029000.0 in Q4 2025, and 178597000.0 in Q3 2025.